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ABSTRACT
Recently published studies clearly indicate that there
are now several acceptable options for managing stage
I testicular seminoma patients after orchiectomy. We
therefore decided to survey Canadian radiation
oncologists to determine how they currently manage
such patients and to compare the results with previ-
ous surveys.
Our results demonstrate that adjuvant single-agent
chemotherapy is being considered as an option by an
increasing proportion of radiation oncologists (although
it is not considered the preferred option), the routine
use of radiotherapy is declining, and surveillance is
becoming increasingly popular and is recommended
most often.
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1. INTRODUCTION
Testicular cancers are the most common—and the most
curable—malignancies among young men in North
America 1,2. Seminomas account for approximately
half of these cancers, and most patients (80%) present
with stage I disease 3,4. Treatment is highly success-
ful, with 5-year overall and disease-specific survivals
approaching 100% for stage I seminoma 2,5.
For decades, the standard treatment for this can-
cer has been radical inguinal orchiectomy, followed
by adjuvant radiotherapy to the para-aortic and ipsilat-
eral pelvic regions 2,5,6. This approach led to a recur-
rence rate of less than 5%, with salvage chemotherapy
being highly effective in the few patients that did re-
lapse 2,3,5,6. However, long-term follow-up data (be-
yond 10–15 years) now indicate that treatment-related
morbidity and mortality (especially from a second
malignancy) are significant concerns 3,7,8. Various ap-
proaches have therefore been investigated to minimize
the toxicity associated with routine use of radiotherapy.
Contemporary management of
stage I testicular seminoma: a
survey of Canadian radiation
oncologists
R. Samant MD,* I. Alomary MD,* P. Genest MD,*
and L. Eapen MD
One approach has been to minimize toxicity by reduc-
ing radiotherapy field sizes and doses 9,10; another ap-
proach has been to avoid radiation altogether 3. This
change has, in turn, resulted in the evolution of surveil-
lance after orchiectomy as a viable option because of
the general availability of computed tomography (CT)
imaging for follow-up purposes 11. In addition, the use
of single-agent chemotherapy (most commonly 1–2
cycles of carboplatin) has also been recognized as a
potential option in place of radiotherapy 12–14.
As a result, management of stage I seminoma is
currently focused not only on maintaining high rates of
cure, but also minimizing both short- and long-term
toxicity 3,11,15. Previously, a survey of radiation on-
cologists conducted by Choo et al. in 2001 regarding
management of stage I seminoma revealed consider-
able variation in practice, especially with regard to
treatment 16. Most radiation oncologists at that time
routinely discussed surveillance as an option, but
thought that only 20% of patients would choose that
option. At that time, the authors found that adjuvant
radiotherapy was usually the preferred choice. How-
ever, data have continued to accumulate regarding the
viability of options that do not include the routine use
of adjuvant radiotherapy.
Review of seminoma management at our own in-
stitution 17 showed a steady decline in the use of adju-
vant radiotherapy since the 1990s and the increasing
use of surveillance for stage I seminoma patients—a
trend that has also been reported elsewhere 18,19. Al-
though recent studies suggest that the use of single-
agent chemotherapy with carboplatin is very
encouraging and the use of adjuvant chemotherapy is
becoming increasingly popular in Europe 20, this ap-
proach is still not routinely considered at our institu-
tion. Our experience has been that chemotherapy tends
to be reserved for the salvage of radiotherapy failures
or in patients wanting adjuvant treatment who are not
deemed suitable for radiation. Based on the increasing
options for management of stage I seminoma, we de-
cided to survey Canadian radiation oncologists to see
if their management approaches had changed since
earlier in the decade.SAMANT et al.
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2. METHODS
We developed an electronic survey to assess manage-
ment of stage I testicular seminoma patients. The sur-
vey was specifically designed for radiation oncologists,
and the categories evaluated included staging investi-
gations, treatment options, radiotherapy treatment plan-
ning details, surveillance protocols, and respondent
demographic information. Intended for self-completion,
the survey takes approximately 15 minutes to finish.
After obtaining approval from the research ethics board
of the Ottawa Hospital to proceed with this survey study,
we sent the survey by e-mail in 2005 to Canadian ra-
diation oncologists identified as treating genitourinary
malignancies. The list of radiation oncologists was for-
mulated from information obtained from the directory
of the Canadian Association of Radiation Oncologists
at that organization’s Web site and from correspon-
dence with radiation oncology department heads at
cancer centres across Canada. Initial non-responders
were sent reminder notices, also by e-mail. Remunera-
tion was not offered for completing the survey.
The completed surveys were collated and analyzed
for this study. The chi-square statistic was used to as-
sess associations between the respondent’s practice
history and that person’s responses to survey questions.
To compare differences in choice of treatment attrib-
utable to age and years of practice, a test of mean dif-
ferences was applied using analysis of variance. The
SPSS software package (SPSS, Chicago, IL, U.S.A.)
was used to perform the analyses.
3. RESULTS
Electronic surveys were sent to 119 Canadian radia-
tion oncologists, and 93 responses were received (78%
response rate). Of the respondents, 14 indicated that
they did not treat seminoma patients, and 1 declined to
complete the survey. The survey completion rate among
eligible responders was therefore 74% (78/105). Among
respondents completing the survey, 89% were men and
11% were women. Median age was 43 years. Mean
length of practice was 13 years, and 80% of the re-
spondents worked in academic centres.
Figure 1 shows that the staging investigations most
commonly used are CT scans of the abdomen and pel-
vis (100%) and chest radiographs (84%). Serum tumour
markers are also commonly assessed, with alpha-
fetoprotein (AFP) being measured 95% of the time, and
beta–human chorionic gonadotropin (bHCG) levels 100%
of the time.
Adjuvant radiation and surveillance were consid-
ered the most common standard treatment options by
90% and 81% of respondents respectively. However,
30% of respondents also listed adjuvant chemotherapy
as a standard treatment option (Figure 2). However,
when asked to indicate the management that they felt
was most appropriate for most patients, surveillance was
chosen by 56%; radiotherapy, by 31%; and chemotherapy,
by 1%. The remaining 12% were unsure of the most
appropriate management (Figure 3). The most common
concerns related to the use of adjuvant radiotherapy were
second cancers (84%), infertility (77%), late gastrointes-
tinal toxicity (67%), acute nausea and vomiting (61%),
and late renal toxicity (60%).
Most respondents (91%) said that they routinely
discuss surveillance with patients, but that tumour-re-
lated risk factors (size, local extension, and
lymphovascular invasion), together with patient age and
compliance, influence their recommendations. Nearly
all respondents (>95%) started offering surveillance
during the last 10 years. Most respondents felt that at
least 50% of patients are now choosing surveillance.
The most commonly listed reasons, in order of impor-
tance, for not offering surveillance were patient fears
and anxieties, patient reluctance, increased costs, and
the belief that survival was actually better with the use
of adjuvant radiotherapy.
For patients on surveillance protocols, the investi-
gations commonly used are CT scans of the abdomen
and pelvis (93%), chest radiographs (81%), bHCG lev-
els (92%), and AFP levels (84%). Surveillance investi-
gations are usually carried out every 3–4 months by
84% of respondents, every 6 months by 15%, and ev-
ery 12 months by 1%.
When treating with radiotherapy, 50% use para-
aortic fields only, and 50% use para-aortic and ipsilat-
eral pelvic fields. Planning CT is used for simulation
by all respondents (100%); intravenous pyelograms and
lymph angiograms are used by only 1%. A dose of 2500
cGy in 15–20 fractions over 3–4 weeks was recom-
mended by more than 90% of respondents, and all re-
spondents use linear accelerators (≥ 6 MV photons)
for treatment delivery. Scrotal shielding is routinely used
by 49% of respondents to reduce dose to the contralat-
eral testicle, and thermoluminescent dosimeters are
used by 47% for verifying dose to the contralateral tes-
ticle. Almost all respondents (96%) discussed fertility
FIGURE 1 The frequency of specific staging investigations used for
stage I seminoma patients, from a sample of Canadian radiation
oncologists. CT = computed tomography; AFP = alpha-fetoprotein;
β-HCG = beta–human chorionic gonadotropin.
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issues and sperm banking with patients before the start
of adjuvant radiotherapy.
Prophylactic antiemetics are ordered by 58% of
the respondents, with ondansetron, prochlorperazine,
dimenhydrinate, and metoclopramide being prescribed
by 48%, 25%, 18%, and 8% respectively. Following
treatment, 67% recommend that patients take contra-
ceptive measures for at least 3 months (14%), 6 months
(38%), 12 months (40%), or 24 months (8%).
We observed a trend, although not statistically sig-
nificant, for older radiation oncologists (> 45 years vs.
≤ 45 years) to choose radiation for their patients (p =
0.07). However, years in practice, type of practice (aca-
demic vs. community), and provincial location did not
appear to influence management choices.
4. DISCUSSION
Cancer treatment approaches evolve with time and
accumulation of research findings—first to improve
and maximize cure rates, and then to minimize toxic-
ity. Stage I seminoma management certainly confirms
this paradigm. The use, since the 1960s, of adjuvant
radiotherapy after orchiectomy reduced relapse rates
to less than 5% and established adjuvant radiation as
the standard practice until the 1990s 2,6. In fact, over-
all 5-year survival rates were in the 98%–99% range,
because chemotherapy was highly successful in sal-
vaging the few patients that did relapse post  radio-
therapy 20. However, with the accumulation of long-term
follow-up data over 25 years or more, it became obvi-
ous that second malignancies are a significant prob-
lem following radiation 3,7. The prevailing focus
therefore moved to reduction of toxicity, because sal-
vage therapies were so effective 3,6.
This change in focus led to numerous studies evalu-
ating alternatives to standard radiotherapy, and reduc-
tions in radiotherapy treatment volumes and lower
radiation doses were both shown to be possible with-
out significantly reducing efficacy 9,10. In prospec-
tive and retrospective studies, surveillance approaches
have also been shown to be an excellent alternative
that do not compromise cure rates, although they re-
quire more frequent imaging investigations 11,17–19.
More recently, the use of adjuvant single-agent che-
motherapy (most commonly with single-agent
carboplatin) has been shown to yield results, in terms
of relapse rates and overall survival, similar to those
seen with the use of adjuvant radiation 14. Therefore,
currently, there is evidence that all of the above ap-
proaches are effective and reasonable options that
have their own unique advantages and limitations.
However, long-term follow-up data for the newer ap-
proaches are limited, and questions still exist regard-
ing long-term efficacy and toxicity.
The effect of recent studies and their influence on
actual current practice patterns across North America
and Europe has not been fully evaluated. However, it
is well known that medical practice patterns often
change gradually after research findings are published,
as physicians reflect on the available evidence and
perhaps discuss them with their colleagues 21–23.
Therefore, we believe that it is important to determine
whether the accumulating evidence regarding manage-
ment of stage I testicular seminoma has had an effect
at the level of clinical practice in Canada, and that is
what we attempted to do in the present study.
With a very favourable survey completion rate of
74% 24, we believe that our results generally reflect
current opinion among Canadian radiation oncologists
regarding stage I seminoma management. Our find-
ings show that staging is fairly consistent and reflects
the emergence of CT scans of the abdomen and pelvis
as standard, together with chest radiographs 11 and se-
rum tumour markers (AFP, bHCG). Radiation treatment
planning with CT scans and delivery approaches using
linear accelerators, as indicated by the respondents,
are also consistent with the published literature, as are
the dose and fractionation regimens commonly used 5.
However, opinion continues to vary regarding the ne-
cessity of ipsilateral pelvic lymph node irradiation.
The surveillance protocols among respondents are
very similar to published recommendations 15. Although
variations in practice still occur, a preponderance of
respondents indicate that they routinely discuss both
surveillance and adjuvant radiotherapy with their
FIGURE 2 Standard management options used for stage I seminoma
patients, from a sample of Canadian radiation oncologists.
FIGURE 3 The “most appropriate option” for most stage I seminoma
patients, from a sample of Canadian radiation oncologists.
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patients, and most believe that surveillance is the pre-
ferred option, with at least 50% of patients making the
latter choice.
Adjuvant chemotherapy is also starting to be rec-
ognized as a treatment option by almost one third of
radiation oncologists even though our survey was con-
ducted before the results of the Medical Research
Council E19 study, published by Oliver et al. 14, indi-
cated that at a median follow-up of 4 years, adjuvant
single-agent carboplatin chemotherapy was essentially
equivalent in terms of relapse rates and overall sur-
vival to adjuvant radiotherapy. Our finding in this re-
gard represents a major shift from the survey results
reported in 2002 by Choo et al. 16, when most radiation
oncologists thought that adjuvant radiotherapy should
be standard, although surveillance was considered an
option. Also, chemotherapy was not even considered
an option by any respondents at that time, likely re-
flecting the limited published data to that point.
The biggest issue remains the attempt to achieve a
balance between minimizing relapse rates and patient
fears and anxiety related to recurrences, and avoiding
unnecessary treatment for the preponderance of pa-
tients that will not relapse and the potential for toxicity
that can occur decades later. This balance will likely
remain controversial for some time to come, and it is
uncertain whether consensus can be achieved in the
near future. Individual patient factors, including per-
sonal choice, will also be essential in determining the
management option that is chosen. However, it is re-
assuring to confirm that many radiation oncologists have
been re-evaluating their approach to management of
stage I testicular seminomas over the last 5 years, in
parallel with growing evidence of newer management
approaches. This re-evaluation may in part be attribut-
able to the growing sub-specialization among many prac-
ticing radiation oncologists in terms of site-specific
treatment and the resulting familiarity with recently
published studies, and also to the Canadian sources of
much of the published literature regarding surveillance
for management of stage I seminoma 11,17–19. We ex-
pect that management approaches will continue to evolve
as ongoing studies mature, especially those evaluating
the use of single-agent carboplatin chemotherapy.
5. CONCLUSIONS
Canadian radiation oncologists are routinely discuss-
ing surveillance in addition to adjuvant radiotherapy as
treatment options for patients with stage I testicular
seminoma, but surveillance is usually considered the
preferred option. Chemotherapy also appears to be
emerging as a viable option among a growing number
of radiation oncologists. As a result, the use of radia-
tion is declining.
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